# Vistagen Therapeutics, Inc.: financial statements, quarterly

VTGN · Nasdaq · CIK 1411685 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Mar 31

Pages: [Overview](/companies/vtgn.md) · [Financials](/companies/vtgn/financials.md) · [Filings](/companies/vtgn/filings.md) · [Insiders](/companies/vtgn/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/vtgn/financials.md?period=annual).

## Income statement

| Line item | Unit | Q2 FY2024 (2023-09-30) | Q3 FY2024 (2023-12-31) | Q4 FY2024 (2024-03-31) | Q1 FY2025 (2024-06-30) | Q2 FY2025 (2024-09-30) | Q3 FY2025 (2024-12-31) | Q4 FY2025 (2025-03-31) | Q1 FY2026 (2025-06-30) | Q2 FY2026 (2025-09-30) | Q3 FY2026 (2025-12-31) | Q4 FY2026 (2026-03-31) | Q1 FY2027 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.3](/filings/0001411685-24-000048.md) | [0.4](/filings/0001411685-25-000019.md) | [0.2 d](/filings/0001411685-25-000041.md) | [0.1](/filings/0001411685-25-000064.md) | [0.2](/filings/0001628280-25-052079.md) | [0.2](/filings/0001628280-26-007718.md) | [(0.0) d](/filings/0001628280-26-043271.md) | [0.2](/filings/0001628280-26-057116.md) | [0.3](/filings/0001628280-25-052079.md) | [0.3](/filings/0001628280-26-007718.md) | [0.5 d](/filings/0001628280-26-043271.md) | [1.5](/filings/0001628280-26-057116.md) |
| Research and development | $m | [3.9](/filings/0001411685-24-000048.md) | [4.5](/filings/0001411685-25-000019.md) | [7.4 d](/filings/0001411685-25-000041.md) | [7.6](/filings/0001411685-25-000064.md) | [10.2](/filings/0001628280-25-052079.md) | [11.3](/filings/0001628280-26-007718.md) | [10.2 d](/filings/0001628280-26-043271.md) | [11.7](/filings/0001628280-26-057116.md) | [15.9](/filings/0001628280-25-052079.md) | [14.2](/filings/0001628280-26-007718.md) | [13.1 d](/filings/0001628280-26-043271.md) | [10.9](/filings/0001628280-26-057116.md) |
| Operating income | $m | [(6.8)](/filings/0001411685-24-000048.md) | [(7.9)](/filings/0001411685-25-000019.md) | [(11.4) d](/filings/0001411685-25-000041.md) | [(12.1)](/filings/0001411685-25-000064.md) | [(14.2)](/filings/0001628280-25-052079.md) | [(15.1)](/filings/0001628280-26-007718.md) | [(14.5) d](/filings/0001628280-26-043271.md) | [(15.8)](/filings/0001628280-26-057116.md) | [(20.1)](/filings/0001628280-25-052079.md) | [(19.5)](/filings/0001628280-26-007718.md) | [(16.7) d](/filings/0001628280-26-043271.md) | [(13.3)](/filings/0001628280-26-057116.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [0.0](/filings/0001411685-24-000048.md) | [0.0](/filings/0001411685-25-000019.md) | [0.0 d](/filings/0001411685-25-000041.md) | [0.0](/filings/0001411685-25-000064.md) | [0.0](/filings/0001628280-25-052079.md) | [0.0](/filings/0001628280-26-007718.md) | [0.0 d](/filings/0001628280-26-043271.md) | [0.0](/filings/0001628280-26-057116.md) | [0.0](/filings/0001628280-25-052079.md) | [0.0](/filings/0001628280-26-007718.md) | [0.0 d](/filings/0001628280-26-043271.md) | [0.0](/filings/0001628280-26-057116.md) |
| Net income | $m | [(6.6)](/filings/0001411685-25-000019.md) | [(6.4)](/filings/0001411685-25-000019.md) | [(9.5) d](/filings/0001411685-25-000041.md) | [(10.7)](/filings/0001628280-26-007718.md) | [(13.0)](/filings/0001628280-26-007718.md) | [(14.1)](/filings/0001628280-26-007718.md) | [(13.6) d](/filings/0001628280-26-043271.md) | [(15.1)](/filings/0001628280-26-057116.md) | [(19.4)](/filings/0001628280-26-007718.md) | [(18.9)](/filings/0001628280-26-007718.md) | [(16.3) d](/filings/0001628280-26-043271.md) | [(13.0)](/filings/0001628280-26-057116.md) |
| Diluted EPS | $ per share | [(0.66)](/filings/0001411685-24-000048.md) | [(0.22)](/filings/0001411685-25-000019.md) | not reported | [(0.35)](/filings/0001411685-25-000064.md) | [(0.42)](/filings/0001628280-25-052079.md) | [(0.46)](/filings/0001628280-26-007718.md) | not reported | [(0.47)](/filings/0001628280-26-057116.md) | [(0.54)](/filings/0001628280-25-052079.md) | [(0.45)](/filings/0001628280-26-007718.md) | not reported | [(0.30)](/filings/0001628280-26-057116.md) |
| Basic EPS | $ per share | [(0.66)](/filings/0001411685-24-000048.md) | [(0.22)](/filings/0001411685-25-000019.md) | not reported | [(0.35)](/filings/0001411685-25-000064.md) | [(0.42)](/filings/0001628280-25-052079.md) | [(0.46)](/filings/0001628280-26-007718.md) | not reported | [(0.47)](/filings/0001628280-26-057116.md) | [(0.54)](/filings/0001628280-25-052079.md) | [(0.45)](/filings/0001628280-26-007718.md) | not reported | [(0.30)](/filings/0001628280-26-057116.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q2 FY2024 (2023-09-30) | Q3 FY2024 (2023-12-31) | FY2024 (2024-03-31) | Q1 FY2025 (2024-06-30) | Q2 FY2025 (2024-09-30) | Q3 FY2025 (2024-12-31) | FY2025 (2025-03-31) | Q1 FY2026 (2025-06-30) | Q2 FY2026 (2025-09-30) | Q3 FY2026 (2025-12-31) | FY2026 (2026-03-31) | Q1 FY2027 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [37.6](/filings/0001437749-23-031293.md) | [127](/filings/0001437749-24-003916.md) | [119](/filings/0001411685-25-000041.md) | [103](/filings/0001411685-24-000037.md) | [84.2](/filings/0001411685-24-000048.md) | [74.7](/filings/0001411685-25-000019.md) | [67.1](/filings/0001628280-26-043271.md) | [49.0](/filings/0001411685-25-000064.md) | [62.8](/filings/0001628280-25-052079.md) | [47.4](/filings/0001628280-26-007718.md) | [30.8](/filings/0001628280-26-057116.md) | [17.0](/filings/0001628280-26-057116.md) |
| Current assets | $m | [39.1](/filings/0001437749-23-031293.md) | [128](/filings/0001437749-24-003916.md) | [121](/filings/0001411685-25-000041.md) | [111](/filings/0001411685-24-000037.md) | [99.9](/filings/0001411685-24-000048.md) | [89.9](/filings/0001411685-25-000019.md) | [82.1](/filings/0001628280-26-043271.md) | [66.7](/filings/0001411685-25-000064.md) | [78.9](/filings/0001628280-25-052079.md) | [63.2](/filings/0001628280-26-007718.md) | [46.9](/filings/0001628280-26-057116.md) | [34.3](/filings/0001628280-26-057116.md) |
| Total assets | $m | [42.2](/filings/0001437749-23-031293.md) | [131](/filings/0001437749-24-003916.md) | [124](/filings/0001411685-25-000041.md) | [114](/filings/0001411685-24-000037.md) | [102](/filings/0001411685-24-000048.md) | [92.3](/filings/0001411685-25-000019.md) | [84.3](/filings/0001628280-26-043271.md) | [68.9](/filings/0001411685-25-000064.md) | [80.9](/filings/0001628280-25-052079.md) | [65.1](/filings/0001628280-26-007718.md) | [48.6](/filings/0001628280-26-057116.md) | [35.7](/filings/0001628280-26-057116.md) |
| Current liabilities | $m | [2.9](/filings/0001437749-23-031293.md) | [4.2](/filings/0001437749-24-003916.md) | [5.1](/filings/0001411685-25-000041.md) | [6.2](/filings/0001411685-24-000037.md) | [7.5](/filings/0001411685-24-000048.md) | [9.6](/filings/0001411685-25-000019.md) | [12.6](/filings/0001628280-26-043271.md) | [11.2](/filings/0001411685-25-000064.md) | [13.6](/filings/0001628280-25-052079.md) | [13.5](/filings/0001628280-26-007718.md) | [12.8](/filings/0001628280-26-057116.md) | [11.2](/filings/0001628280-26-057116.md) |
| Total liabilities | $m | [6.6](/filings/0001437749-23-031293.md) | [7.8](/filings/0001437749-24-003916.md) | [9.4](/filings/0001411685-25-000041.md) | [8.7](/filings/0001411685-24-000037.md) | [9.5](/filings/0001411685-24-000048.md) | [11.2](/filings/0001411685-25-000019.md) | [14.0](/filings/0001628280-26-043271.md) | [12.2](/filings/0001411685-25-000064.md) | [14.6](/filings/0001628280-25-052079.md) | [14.1](/filings/0001628280-26-007718.md) | [13.0](/filings/0001628280-26-057116.md) | [11.3](/filings/0001628280-26-057116.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Short-term borrowings | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [35.6](/filings/0001411685-25-000019.md) | [123](/filings/0001411685-25-000019.md) | [114](/filings/0001628280-26-043271.md) | [105](/filings/0001628280-26-007718.md) | [93.0](/filings/0001628280-26-007718.md) | [81.1](/filings/0001628280-26-007718.md) | [70.4](/filings/0001628280-26-057116.md) | [56.8](/filings/0001628280-26-057116.md) | [66.3](/filings/0001628280-26-007718.md) | [50.9](/filings/0001628280-26-007718.md) | [35.5](/filings/0001628280-26-057116.md) | [24.5](/filings/0001628280-26-057116.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Current portion of debt: not reported
- Short-term borrowings: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q2 FY2024 (2023-09-30) | Q3 FY2024 (2023-12-31) | Q4 FY2024 (2024-03-31) | Q1 FY2025 (2024-06-30) | Q2 FY2025 (2024-09-30) | Q3 FY2025 (2024-12-31) | Q4 FY2025 (2025-03-31) | Q1 FY2026 (2025-06-30) | Q2 FY2026 (2025-09-30) | Q3 FY2026 (2025-12-31) | Q4 FY2026 (2026-03-31) | Q1 FY2027 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(6.2) d](/filings/0001411685-24-000048.md) | [(4.7) d](/filings/0001411685-25-000019.md) | [(7.0) d](/filings/0001411685-25-000041.md) | [(10.9)](/filings/0001411685-25-000064.md) | [(10.9) d](/filings/0001628280-25-052079.md) | [(10.3) d](/filings/0001628280-26-007718.md) | [(10.1) d](/filings/0001628280-26-043271.md) | [(18.8)](/filings/0001628280-26-057116.md) | [(13.8) d](/filings/0001628280-25-052079.md) | [(17.6) d](/filings/0001628280-26-007718.md) | [(16.2) d](/filings/0001628280-26-043271.md) | [(14.7)](/filings/0001628280-26-057116.md) |
| Capital expenditure | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: not reported

## Shares

| Line item | Unit | Q2 FY2016 (2015-09-30) | Q3 FY2016 (2015-12-31) | Q1 FY2024 (2023-06-30) | Q2 FY2024 (2023-09-30) | Q3 FY2024 (2023-12-31) | Q1 FY2025 (2024-06-30) | Q2 FY2025 (2024-09-30) | Q3 FY2025 (2024-12-31) | Q1 FY2026 (2025-06-30) | Q2 FY2026 (2025-09-30) | Q3 FY2026 (2025-12-31) | Q1 FY2027 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [1.6](/filings/0001415889-15-003716.md) | [1.8](/filings/0001415889-16-004781.md) | [7.3](/filings/0001411685-24-000037.md) | [10.0](/filings/0001411685-24-000048.md) | [29.4](/filings/0001411685-25-000019.md) | [30.6](/filings/0001411685-25-000064.md) | [30.6](/filings/0001628280-25-052079.md) | [30.7](/filings/0001628280-26-007718.md) | [31.9](/filings/0001628280-26-057116.md) | [35.7](/filings/0001628280-25-052079.md) | [42.2](/filings/0001628280-26-007718.md) | [43.0](/filings/0001628280-26-057116.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 44,376,911 at 2026-08-10, from the cover of the [10-Q filed 2026-08-14](/filings/0001628280-26-057116.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:39 ET. No prices; not investment advice.